RxDoctor Payments Data

Norman Burns, MD

Neurology · Rochester Hills, MINPI 1891793402

Payments from drug & device makers

$32,680in general payments, 2019–2025

Across 2,008 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novartis$2K
  • Biogen$2K
  • UCB, Inc.$2K
  • Bristol Myers Squibb$2K
  • EMD Serono, Inc.$1K
  • plus $18K from 54 others

What the payments were for

  • Speaking & faculty fees$1,6125%
  • Travel & lodging$5452%
  • Food & beverage$30,08892%
  • Education$4351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)192$4,723
Novartis272$2,484
Biogen98$1,915
UCB, Inc.131$1,768
Bristol Myers Squibb103$1,553
EMD Serono, Inc.79$1,362
Amgen(2 entities)81$1,326
Supernus Pharmaceuticals, Inc.86$1,187
Sanofi54$966
Neurocrine Biosciences, Inc.43$899
Pfizer61$887
Johnson & Johnson(2 entities)56$849
Eisai Inc.43$820
Lundbeck LLC50$813
Argenx US, Inc.43$733
TG Therapeutics, Inc.28$697
Lilly USA, LLC56$656
Genentech USA, Inc.32$573
Teva Pharmaceuticals USA, Inc.46$487
Catalyst Pharmaceuticals, Inc.23$484
Jazz Pharmaceuticals Inc.27$461
Acadia Pharmaceuticals Inc33$440
AstraZeneca(2 entities)22$436
Amneal Pharmaceuticals LLC22$393
SK Life Science, Inc.17$385
Harmony Biosciences LLC15$350
Neurelis, Inc.21$336
Kyowa Kirin, Inc.18$317
Avanir Pharmaceuticals, Inc.16$258
ANI Pharmaceuticals, Inc.8$256
Alnylam Pharmaceuticals Inc.14$231
Sunovion Pharmaceuticals Inc.16$228
Corium, LLC17$220
MDD US Operations, LLC17$219
Sumitomo Pharma America, Inc.13$210
Acorda Therapeutics, Inc11$176
Vanda Pharmaceuticals Inc.8$152
CSL Behring9$149
Biohaven Pharmaceutical Holding Company Ltd.10$147
Adamas Pharmaceuticals, Inc.7$131
Otsuka America Pharmaceutical, Inc.8$126
Scilex Pharmaceuticals Inc.6$126
Impel Pharmaceuticals Inc.7$119
Mallinckrodt Hospital Products Inc.7$118
E.r. Squibb & Sons, L.L.C.5$105
Octapharma USA, Inc.4$102
Cycle Pharmaceuticals Inc5$101
Takeda Pharmaceuticals U.S.A., Inc.4$91
Biohaven Pharmaceuticals, Inc.5$77
Banner Life Sciences, LLC3$74
Nevro Corp.4$65
Aucta Pharmaceuticals, Inc.5$64
Zogenix Inc.4$62
Greenwich Biosciences, Inc.4$59
Akcea Therapeutics, Inc.3$53
Cala Health, Inc.3$52
Azurity Pharmaceuticals, Inc.3$50
Tanabe Pharma America, Inc.3$47
Xeris Pharmaceuticals, Inc.2$46
Abbott2$46

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,680 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$164,108
Medicare patients
503
Services billed
4,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide13$119,796
FingolimodFingolimod Hcl25$96,400
BriviactBrivaracetam47$74,563
Nurtec OdtRimegepant Sulfate43$70,078
UbrelvyUbrogepant50$68,815
CopaxoneGlatiramer Acetate11$63,122
NuplazidPimavanserin Tartrate12$55,844
Aimovig AutoinjectorErenumab-Aooe67$51,876
AptiomEslicarbazepine Acetate28$45,842
Emgality PenGalcanezumab-Gnlm53$45,577
QuliptaAtogepant26$29,846
Teriflunomide12$25,196
Trokendi XrTopiramate18$20,657
NuedextaDextromethorphan Hbr/Quinidine12$17,485
FycompaPerampanel19$17,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$966$119,79613 claims
AbbVieUbrelvy, Qulipta$4,723$98,66176 claims
UCB, Inc.Briviact$1,768$74,56347 claims
PfizerNurtec Odt$887$70,07843 claims
Teva Pharmaceuticals USA, Inc.Copaxone$487$63,12211 claims
Acadia Pharmaceuticals IncNuplazid$440$55,84412 claims
Sunovion Pharmaceuticals Inc.Aptiom$228$45,84228 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$1,187$20,65718 claims
Avanir Pharmaceuticals, Inc.Nuedexta$258$17,48512 claims
Eisai Inc.Fycompa$820$17,23119 claims
Corium, LLCAdlarity$220$7,99718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →